Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
Please note the ANZCTR will be unattended on Monday the 7th of October for the Labour Day public holiday.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12620001286932
Ethics application status
Approved
Date submitted
24/08/2020
Date registered
27/11/2020
Date last updated
12/05/2023
Date data sharing statement initially provided
27/11/2020
Type of registration
Prospectively registered
Titles & IDs
Public title
Investigating the effect of a virus-based immunotherapy as a pre-surgical treatment for prostate cancer
Query!
Scientific title
Neoadjuvant Study of the effect of Intratumoural and Intravenous Pexastimogene Devacirepvec (Pexa-Vec) on CD8-based anti-tumour response in Prostate Cancer Prior to Radical Prostatectomy
Query!
Secondary ID [1]
302060
0
Nil
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
IMPROVE
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Prostate Cancer
318660
0
Query!
Condition category
Condition code
Cancer
316679
316679
0
0
Query!
Prostate
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Arm 1: MRI-guided intratumoural (IT) Pexastimogene Devacirepvec (Pexa-Vec) (1x109 PFU) x 1 dose (Day 1). Radical prostatectomy will be performed 29-43 days following the IT injection. The MRI-guided injection will be performed by a specialised radiologist with previous experience and training in this procedure. Overall study duration for participants in this arm is 119-133 days.
Arm 2: MRI-guided intratumoural Pexastimogene Devacirepvec (Pexa-Vec) (1x109 PFU) x 2 doses (Day 1, 15). Radical prostatectomy will be performed 43-57 days after the first IT injection. The MRI-guided injection will be performed by a specialised radiologist with previous experience and training in this procedure. Overall study duration for participants in this arm is 133 - 147 days.
Arm 3: Systemic intravenous (IV) infusion Pexastimogene Devacirepvec (Pexa-Vec) (1x109 PFU) x 2 doses (Day 1, 8). The IV infusion will be performed by a medical oncologist and clinical research coordinator. Radical prostatectomy will be performed 36-50 days after the first IV infusion. Overall study duration for participants in this arm is 126-140 days.
For all arms of the study adherence to the intervention will be monitored by the Data and Safety Monitoring Committee and central medical review of source documents. Laboratory tests and clinical reviews will be performed 7 days after each treatment.
Query!
Intervention code [1]
318362
0
Treatment: Drugs
Query!
Comparator / control treatment
No control group
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
324804
0
Composite primary outcome - evaluate the effect of neoadjuvant treatment with Intratumoural (IT) Pexa-Vec oncolytic virus on CD8-based anti-tumour response in prostate cancer.
Defined as the proportion patients with a greater than or equal to 30% increase in the proportion of CD8+ (and/or CD45RO+) T-cells in the radical prostatectomy specimen compared to that of the baseline prostate biopsy.
Query!
Assessment method [1]
324804
0
Query!
Timepoint [1]
324804
0
Composite primary outcome 1 assessed:
1) During the Treatment Phase - Fresh tumour biopsy at screening for cohorts 1 and 2 patients only prior to the first IT injection.
-Fresh tumour Biopsy collected in cohort 2 patients only at the time of the second IT injection.
2) At time of surgery 29 – 57 days after the completion of Pexa-Vec treatment.
Query!
Primary outcome [2]
324805
0
Composite primary outcome - evaluate the effect of neoadjuvant treatment with intravenous Pexa-Vec oncolytic virus on CD8-based anti-tumour response in prostate cancer.
Defined as the proportion patients with a greater than or equal to 30% increase in the proportion of CD8+ (and/or CD45RO+) T-cells in the radical prostatectomy specimen compared to that of the baseline prostate biopsy.
Query!
Assessment method [2]
324805
0
Query!
Timepoint [2]
324805
0
Composite primary outcome 2 assessed:
1) At time of surgery 36 – 50 days after the completion of Pexa-Vec treatment.
Query!
Primary outcome [3]
324806
0
To assess the safety and tolerability of neoadjuvant treatment with IT and IV Pexa-Vec oncolytic virus in patients undergoing radical prostatectomy.
Defined as the proportion of patients who develop one of the following during the treatment and follow up periods:
- Dose-limiting toxicity (DLS) graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5 (NCI CTCAE v5).
DLS is defined as one of the following toxicities occurring during the first 28 days following the initial Pexa-Vec oncolytic virus injection in cohort 1 and 28 days after the second Pexa-Vec oncolytic virus IT injection/IV infusion in cohort 2 and 3:
• Grade 4 hematological toxicity lasting greater than or equal to 7 days except:
- Grade 4 lymphopaenia without clinically relevant sequelae
- Grade 4 thrombocytopaenia not associated with a clinically significant bleeding event
• All Grade 3 and Grade 4 non-haematologic toxicity that represent a 2-grade increase
over baseline except:
- Grade 3 flu-like symptoms (specifically fatigue, malaise, headache, and myalgia)
lasting <14 days
- Grade 3–4 fever lasting <3 days
- Grade 3 hypotension lasting <24 hours
- Grade 3 nausea, vomiting and diarrhea lasting <7days
- Grade 3 hypothyroidism responsive to hormone therapy
- Grade 3 hyponatraemia without clinical significance
- Grade 3–4 non-haematologic toxicity without clinical significance (e.g., transient,
asymptomatic elevation of amylase or lipase)
• Any Grade 3 or Grade 4 non-haematologic laboratory value if:
- The abnormality leads to hospitalization and requires active intervention
• Grade 3 or greater cardiac toxicity that does not decrease to a Grade 1 event 72 hours
after initiation of maximal supportive care
• Grade 3 and Grade 4 thrombocytopenia with clinically-significant bleeding associated
with Pexa-Vec
• Grade greater than or equal to 3 febrile neutropenia
a. If Grade 3, the event must (in the judgement of the Investigator) be clinically
significant and require intervention (e.g. G-CSF, antibiotic therapy) for resolution of
the event
• Grade 5 toxicity
Assessed using blood tests, physical examination and self reporting.
- Surgical complication of interest
Surgical complications will be assessed according to the Clavien-Dindo classification. A SCOI will be defined as one of the following events occurring at the time surgery or during the following 30 days following surgery:
• Inability to complete radical prostatectomy
• Rectal injury
• Ureteric injury
• Significant blood loss requiring blood transfusion
• Any surgical difficulty or complication which in the opinion of the operating surgeon
may be related to prior PEXA-Vec treatment
- Adverse event
Adverse events will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5 (NCI CTCAE v5).
- Serious adverse event
Adverse events will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5 (NCI CTCAE v5).
Query!
Assessment method [3]
324806
0
Query!
Timepoint [3]
324806
0
DLS - Assessment during the Treatment Phase - day 1, 2, 8, 9, 15, 16 and 22 and during surgery, 14 days, 30 days and 90 days post surgery.
SCOI - Assessed during surgery, 14 days, 30 days and 90 days post surgery.
Query!
Secondary outcome [1]
385789
0
To assess changes within the tumour microenvironment in radical prostatectomy specimens following treatment with IT or IV Pexa-Vec. Assessed by histological examination of fresh and stained prostate specimens following treatment with IT or IV Pexa-Vec.
Query!
Assessment method [1]
385789
0
Query!
Timepoint [1]
385789
0
1) During the Treatment Phase - Fresh tumour biopsy at screening for cohorts 1 and 2 patients
only prior to the first IT injection.
-Fresh tumour Biopsy collected in cohort 2 patients only at the
time of the second IT injection.
2) At time of surgery in all cohorts 29 – 57 days after the completion of Pexa-Vec treatment
Query!
Eligibility
Key inclusion criteria
1. Patient has provided written informed consent
2. Patients with histologically confirmed prostate adenocarcinoma
3. Age greater than or equal to 18 years
4. Suitable for radical prostatectomy in the opinion of the treating surgeon, following results of all screening investigations, including PSMA PET/CT scan
5. Disease detectable on MRI
6. Patient has adequate organ function within 7 days prior to registration as defined as:
White blood cell count (WCC) greater than or equal to 2 x 109/L
Absolute neutrophil count (ANC) greater than or equal to 1 x 109/L
Haemoglobin greater than or equal to 90 g/L
Platelet count greater than or equal to 100 x 109/L
Activated partial thromboplastin time (aPTT) less than or equal to 1.5 ULN
International Normalized Ratio (INR) less than or equal to 1.5 ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 2.5 x ULN unless liver metastases are present, in which case it must be less than or equal to 5 x ULN
Serum sodium 130-150mmol/L
Serum potassium 3.0-5.5mmol/L
Serum Corrected Calcium 2.0-2.9 mmol/L
Serum Creatinine less than or equal to 1.5 ULN or estimated glomerular filtration rate greater than 30mL/min/1.73m2
Oxygen saturation (SaO2) by pulse oximetry greater than 90% at rest
7. For patients who are sexually active with partners of childbearing potential: willing to use double barrier contraception method for at least 6 weeks after each treatment of Pexa-Vec
8. Willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations during both the treatment and follow-up phases
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Males
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Prior anti-cancer therapy for prostate cancer
2. High volume metastatic disease on imaging including PSMA PET/CT as defined by
one or more of the following criteria:
a. The presence of visceral metastases
b. greater than or equal to 4 bone lesions, including greater than or equal to 1 beyond the vertebral bodies and pelvis
3. Low-risk prostate cancer as defined by all of the following criteria
a. PSA < 20ng/ml
b. Gleason score 3+4=7 or equal to or less than 6
c. Clinor equal toical stage < T2c
4. Known immunodeficiency due to underlying illness (e.g., human immunodeficiency
virus [HIV] / acquired immune deficiency syndrome [AIDS]) and/or long-term
immune-suppressive medication including high-dose corticosteroids (defined as >10
mg/day prednisone or equivalent)
5. Known myeloproliferative disorders requiring systemic therapy
6. History of severe inflammatory or exfoliative skin condition (e.g. eczema or ectopic
dermatitis) requiring systemic therapy
7. Tumour in location that would potentially result in significant clinical adverse effects if post-treatment tumour swelling were to occur
8. Tumour invading a major vascular structure or other key anatomical structure
9. Severe or unstable cardiovascular disease, including but not limited to significant
coronary artery disease (e.g., myocardial infarction or other coronary artery disease
requiring angioplasty or stenting) or congestive heart failure within the preceding 12
months
10. Inability to suspend treatment with anti-hypertensive medication (including but not
limited to: diuretics, beta-blockers, angiotensin converting enzyme [ACE] inhibitors,
aldosterone antagonists, etc.) for 48 hours prior to and 48 hours after all Pexa-Vec
treatments
11. Use of anti-viral medications
12. Use of anti-platelet, or anti-coagulation medication that cannot be safely suspended
prior to IT injections
13. Medical conditions that place the patient at risk should tachycardia, hypotension or
volume loading occur during or following treatment with Pexa-Vec
14. Experienced a severe systemic reaction or side-effect as a result of a previous
smallpox vaccination
15. Other medical condition or laboratory abnormality or active infection that in the
judgment of the Investigator may increase the risk associated with study participation
or may interfere with interpretation of study results and/or otherwise make the patient
inappropriate for entry into this study
16. Prior malignancy except for cancer from which the patient has been disease-free for 3
years, or the following: adequately treated basal or squamous cell skin cancer, in situ
carcinoma (including cervical, breast and superficial bladder cancer)
17. Prior or planned organ transplant
18. Use of interferon/pegylated interferon (PEG-IFN) or ribavirin that cannot be
discontinued within 14 days prior to any Pexa-Vec dose
19. Known active Hepatitis B or Hepatitis C
20. Patients must not receive live vaccines, other than Pexa-Vec, within 30 days of
planned start of Pexa-Vec, during the study, and for a minimum of 15 weeks after the
last dose of Pexa-Vec
21. Clinically significant and/or rapidly accumulating ascites, pericardial and/or pleural
effusions
22. Inability to avoid direct physical contact with household contacts who are at high risk if
exposed to Pexa-Vec. High risk patients include any of the following:
a. pregnant or breastfeeding women
b. children <12 months of age
c. immunocompromised individuals (e.g., organ transplant recipients, HIV-positive
individuals, or those receiving chronic immunosuppressive medication)
d. individuals with ongoing severe inflammatory skin condition requiring medical
treatment or history of severe eczema requiring medical treatment
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Other
Query!
Other design features
Recruitment to each cohort will occur in a consecutive manner, with each cohort completing recruitment and ensuring safety, prior to commencement of recruitment to the next cohort. The first cohort to be evaluated will be cohort 1 and will follow a 3 + 3 + 4 recruitment strategy. Recruitment decisions will be made by the Safety Monitoring Committee.
Dose Limiting Toxicities (DLTs) and Surgical Complications of Interest (SCOI) will be monitored over the first 28 days of treatment for DLTs and during the 30 days post-surgical period for SCOIs. After each group of patients within each cohort complete both observation periods, the SMC will meet and review the available safety and toxicity information to determine if recruitment of the next group of patients is to continue.
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Safety/efficacy
Query!
Statistical methods / analysis
Co-primary endpoints will be reported using descriptive statistics. The incidence of adverse events, including serious adverse events will be calculated for each cohort.
Query!
Recruitment
Recruitment status
Recruiting
Query!
Date of first participant enrolment
Anticipated
1/12/2022
Query!
Actual
5/05/2023
Query!
Date of last participant enrolment
Anticipated
30/06/2024
Query!
Actual
Query!
Date of last data collection
Anticipated
31/12/2024
Query!
Actual
Query!
Sample size
Target
30
Query!
Accrual to date
1
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
17308
0
Royal Melbourne Hospital - City campus - Parkville
Query!
Recruitment hospital [2]
17309
0
Frankston Hospital - Frankston
Query!
Recruitment hospital [3]
17310
0
Southwest Health Care - Warrnambool - Warrnambool
Query!
Recruitment hospital [4]
17311
0
Austin Health - Austin Hospital - Heidelberg
Query!
Recruitment hospital [5]
17312
0
Western Hospital - Footscray - Footscray
Query!
Recruitment hospital [6]
17313
0
St Vincent's Hospital (Melbourne) Ltd - Fitzroy
Query!
Recruitment postcode(s) [1]
31038
0
3011 - Footscray
Query!
Recruitment postcode(s) [2]
31034
0
3050 - Parkville
Query!
Recruitment postcode(s) [3]
31039
0
3065 - Fitzroy
Query!
Recruitment postcode(s) [4]
31037
0
3084 - Heidelberg
Query!
Recruitment postcode(s) [5]
31035
0
3199 - Frankston
Query!
Recruitment postcode(s) [6]
31036
0
3280 - Warrnambool
Query!
Funding & Sponsors
Funding source category [1]
306494
0
Charities/Societies/Foundations
Query!
Name [1]
306494
0
Movember
Query!
Address [1]
306494
0
PO Box 60
East Melbourne
VIC 8002
Query!
Country [1]
306494
0
Australia
Query!
Funding source category [2]
306501
0
Government body
Query!
Name [2]
306501
0
Medical Research Future Fund
Query!
Address [2]
306501
0
Department of Health
GPO Box 9848
Canberra ACT 2601
Query!
Country [2]
306501
0
Australia
Query!
Primary sponsor type
Hospital
Query!
Name
Royal Melbourne Hospital
Query!
Address
Grattan St Parkville Vic 3052
Query!
Country
Australia
Query!
Secondary sponsor category [1]
307020
0
None
Query!
Name [1]
307020
0
Query!
Address [1]
307020
0
Query!
Country [1]
307020
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
306687
0
Melbourne Health HREC
Query!
Ethics committee address [1]
306687
0
Grattan St Parkville Vic 3052
Query!
Ethics committee country [1]
306687
0
Australia
Query!
Date submitted for ethics approval [1]
306687
0
10/06/2020
Query!
Approval date [1]
306687
0
16/09/2020
Query!
Ethics approval number [1]
306687
0
Query!
Summary
Brief summary
The purpose of this study is to learn whether injecting Pexa-Vec directly into the prostate cancer or into the blood stream is a safe and useful treatment for patients with prostate cancer, before they undergo standard surgery to remove the prostate gland. Who is it for? You may be eligible for this study if you are aged 18 years or older, have been recently diagnosed with prostate cancer and you haven't received any previous cancer treatments, including surgery, androgen deprivation therapy, chemotherapy or radiotherapy. Study details Participants in this study will have a small sample of prostate tissue (biopsy) taken before they receive any treatment. The first 10 participants will have a single dose of Pexa-Vec modified viral treatment injected directly into their prostate gland while they are in an MRI scanner, at least 4 weeks prior to prostate removal surgery. The second 10 participants will have two doses of Pexa-Vec treatment injected directly into their prostrate gland while they are in an MRI scanner, the first dose will be 6 weeks prior to surgery and the second dose at least 4 weeks prior to surgery. The last 10 participants will have two doses of Pexa-Vec treatment injected into their blood stream, the first dose will be at least 5 weeks prior to surgery and the second dose at least 4 weeks prior to surgery. All participants will undergo prostate removal surgery as scheduled by their doctor and will be asked to attend a series of follow-up appointments for up to 90 days after surgery to discuss their health and any complications they might have had. It is hoped this research may be used to improve health outcomes for future patients with prostate cancer by determining whether Pexa-Vec is safe and effective at changing the appearance of tumour and immune cells, while possibly reducing tumour cell growth prior to prostate removal surgery.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
104678
0
Dr Niall Corcoran
Query!
Address
104678
0
Royal Melbourne Hospital
Grattan Street
Parkville VIC 3052
Query!
Country
104678
0
Australia
Query!
Phone
104678
0
+61 3 9342 7000
Query!
Fax
104678
0
Query!
Email
104678
0
niallmcorcoran@gmail.com
Query!
Contact person for public queries
Name
104679
0
Niall Corcoran
Query!
Address
104679
0
Royal Melbourne Hospital
Grattan Street
Parkville VIC 3052
Query!
Country
104679
0
Australia
Query!
Phone
104679
0
+61 3 9342 7000
Query!
Fax
104679
0
Query!
Email
104679
0
niallmcorcoran@gmail.com
Query!
Contact person for scientific queries
Name
104680
0
Niall Corcoran
Query!
Address
104680
0
Royal Melbourne Hospital
Grattan Street
Parkville VIC 3052
Query!
Country
104680
0
Australia
Query!
Phone
104680
0
+61 3 9342 7000
Query!
Fax
104680
0
Query!
Email
104680
0
niallmcorcoran@gmail.com
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
All data generated from this study will remain confidential and no published report will contains any reference to patient names or patient identifiers.
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF